KRAS and non-small cell lung carcinoma: A clinical report described a patient with KRAS (G12C) NSCLC who developed polyclonal acquired resistance to MRTX849 and showed 10 heterogeneous resistance changes in 4 genes, including KRAS, NRAS, BRAF, and MAP2K1.